JGC
JAZZ icon

J. Goldman & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

J. Goldman & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,700
Closed -$2.42M – 536
2024
Q2 		$2.42M Buy
+22,700
New +$2.5M 0.07% 234
2024
Q1 		– Sell
-11,400
Closed -$1.4M – 458
2023
Q4 		$1.4M Buy
+11,400
New +$1.42M 0.06% 212

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

J. Goldman & Co's JAZZ Position: Q4 2024 in Review

J. Goldman & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2024, closing a stake of 18,969 shares — an estimated $2.11M sold.

J. Goldman & Co first reported a position in JAZZ in Q2 2016 and held it in 12 quarters. The position peaked at $9.54M in Q1 2017. 508 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.

  • J. Goldman & Co reported no remaining Jazz Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • J. Goldman & Co sold 18,969 Jazz Pharmaceuticals shares in Q4 2024, an estimated $2.11M.
  • J. Goldman & Co first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 12 quarters.
  • J. Goldman & Co's Jazz Pharmaceuticals position peaked at $9.54M in Q1 2017.
  • 508 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.

Based on J. Goldman & Co's 13F filing for Q4 2024, filed 14 Feb 2025.